As the first-ever Medicare drug-price negotiations take shape, Big Pharma-backed Democrats want to limit the number of costly medicines regulators can target.
Democratic Reps. Scott Peters (Calif.), Wiley Nickel (N.C.), Josh Gottheimer (N.J.) and Donald Davis (N.C.) are each co-sponsoring at least one of several proposed bills that would limit regulators’ ability to negotiate down prices of drugs covered by the Medicare government insurance program. The legislation would erode the drug-pricing reforms included in the Democrats’ 2022 Inflation Reduction Act — efforts that Peters, Nickel, and Gottheimer supported. (Davis had not yet been elected to Congress.)
The four, who all hail from states with a major biotech or drug-industry presence, have together raked in more than $300,000 from pharmaceutical and health-products interests during the 2023-2024 congressional session. Gottheimer is reportedly eyeing a 2025 gubernatorial run in New Jersey, home to the pharmaceutical giant Merck & Co.
Recent Posts
Abolish the Board of Peace. Try the Table of Peace.
Take Action Now I asked people to pretend to be the United States Congress for 10 seconds. (Many of them were disgusted at the thought but I assured…
Black Power, White Heat, and the Work of Solidarity
Take Action Now What a history of the 1960s can teach us about organizing in an authoritarian ageBy Alexandria Shaner, Z Network There is a…
ICE Bans Hugging Inside California’s Largest Detention Center. Families Are Fighting Back
Take Action Now In the California City facility, ‘contact visits’ are strictly forbidden – but detained residents aren’t staying quiet. Are officials…
Tyrant Trump Is Lucky in the Cowardice of His Enemies
Take Action Now Democratic leadership’s refusal to pursue impeachment signals to Trump that he has two-plus unchallenged years to ravage the lives…